Naltrexone (CAS 16590-41-3)
Alternate Names:
17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
CAS Number:
16590-41-3
Molecular Weight:
341.40
Molecular Formula:
C20H23NO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Naltrexone is recognized for its high affinity for opioid receptors, which makes it useful in the study of the endogenous opioid system. This compound is used to elucidate the binding characteristics and signal transduction pathways of opioid receptors in the nervous system. In addiction studies, it provides a means to investigate the biochemical mechanisms underlying substance dependence and the body′s response to various addictive compounds. Furthermore, naltrexone is instrumental in research on neurochemical behavior related to reward and addiction. Its ability to block opioid receptors is also utilized in studying the modulation of immune responses, as these receptors are implicated in the regulation of immune function.
Naltrexone (CAS 16590-41-3) References
- Optimally Choosing Medication Type for Patients With Opioid Use Disorder. | Rudolph, KE., et al. 2023. Am J Epidemiol. 192: 748-756. PMID: 36549900
- Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. | Andraka-Christou, B., et al. 2023. Ann Med. 55: 514-520. PMID: 36724766
- Shifting the sociometer: opioid receptor blockade lowers self-esteem. | Tchalova, K., et al. 2023. Soc Cogn Affect Neurosci. 18: PMID: 36961732
- Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. | Spreer, M., et al. 2023. Transl Psychiatry. 13: 113. PMID: 37019884
- Low-dose naltrexone in the treatment of fibromyalgia: A systematic review and narrative synthesis. | Aitcheson, N., et al. 2023. Aust J Gen Pract. 52: 189-195. PMID: 37021443
- Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review. | Edinoff, AN., et al. 2023. Curr Pain Headache Rep.. PMID: 37115486
- Education Intervention to Increase Naltrexone Use Among Adult Inpatients With Alcohol Use Disorder. | Ipsarides, J. 2023. J Psychosoc Nurs Ment Health Serv. 1-5. PMID: 37134282
- Climbing behavior by mice as an endpoint for preclinical assessment of drug effects in the absence and presence of pain. | Santos, EJ., et al. 2023. Front Pain Res (Lausanne). 4: 1150236. PMID: 37139343
- Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of Human Adipose-Derived Mesenchymal Stem Cells. | Kazemi, R., et al. 2023. Iran J Immunol. 20: PMID: 37151015
- Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice. | Kumari, R., et al. 2023. Neurochem Res.. PMID: 37166576
- Intramuscular, extended-release naltrexone inadvertently administered in the deltoid muscle: a case report. | Deaney, M. and Terasaki, D. 2023. J Am Pharm Assoc (2003).. PMID: 37207707
- A pharmacologically pre-contracted smooth muscle bowel model for the study of highly-potent opioid receptor agonists and antagonists. | Amend, N., et al. 2023. Toxicol Lett.. PMID: 37245850
- Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. | Stefanakis, K., et al. 2023. Diabetes Obes Metab.. PMID: 37246799
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Naltrexone, 100 mg | sc-477813 | 100 mg | $340.00 | |||
Naltrexone, 1 g | sc-477813A | 1 g | $1353.00 | |||
Naltrexone, 2.5 g | sc-477813B | 2.5 g | $2400.00 |